Compare Enovix Corporation (ENVX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Neurocrine Biosciences Inc — how do they compare? Enovix Corporation trades at $4.82 (market cap $1.11B), while Neurocrine Biosciences Inc trades at $172.22 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 15.6× Enovix Corporation's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | NBIX | |
|---|---|---|
Market Cap | $1.11B | $17.30B |
Sector | Technology | Health |
52-Week High | $15.93 | $180.55 |
52-Week Low | $4.84 | $123.10 |
Enterprise Value | $1.13B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
